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Abstract
Background—CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a
key determinant in breast cancer outcomes. Our study examined patients' beliefs about how
CYP2D6 genotype would affect their prognoses.
Methods—Women enrolled in a pharmacogenomic clinical trial and on tamoxifen for prevention
or treatment of breast cancer underwent CYP2D6 genotyping (EM=extensive, IM=intermediate,
PM=poor metabolizing alleles). The informed consent said that the purpose of the trial was to
examine effects of dose adjustment based on genotype, but that clinical benefits were uncertain.
Our embedded sub-study surveyed 320 patients prior to receiving their genotypes. We
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experimentally manipulated 6 vignettes to describe hypothetical tamoxifen treatment (no or yes)
and hypothetical genotype (EM, IM or PM). For each vignette, women gave their perceived
recurrence risk (RR; 0-100%).
Results—Women believed that genotype would not affect their RR if they did not take
tamoxifen (p=.06). However, women believed that if prescribed tamoxifen, genotype would affect
their RR (22% if EM, 30% if IM and 40% if PM, p<.001).
Conclusion—Women believed that extensive tamoxifen metabolizers had better prognoses,
despite study materials stating uncertainty about any benefit. The rapidly changing nature of
genomic science calls for caution when communicating clinical utility.
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Introduction
New genomic markers will increasingly inform clinical care, but some may become
available to patients prior to clinical validation. Cytochrome P450 2D6 (CYP2D6) is a
critical enzyme in the metabolism of tamoxifen [1-3], however studies are conflicting
regarding CYP2D6 as a tamoxifen efficacy biomarker. For this reason, CYP2D6 genotyping
currently does not meet evidence for clinical use [4]. However, in 2009, when data were just
emerging on this subject, a national community-based survey suggested that one-third of
oncologists had previously ordered CYP2D6 genotyping for use in clinical decision making
[5].
While pharmacogenomics is an emerging area for breast cancer research, little is known
regarding how well patients understand pharmacogenomics or the rationale for clinical trial
research in this area [6]. Our pilot study suggested that after informed consent, a substantial
number of participants reported a strong degree of understanding of pharmacogenomics
research, but remained confused about several aspects of the study [7]. In other areas of
oncology research, trial participants have often expressed high expectations of direct
personal benefit of the intervention, regardless of scientific uncertainty [8,9].
Previous work has shown that, in some cases, women resist or even ignore breast cancer risk
information [10], while other studies show highly accurate responses to risk information
[11]. Thus, it is not clear whether patients would understand the risk information provided
by this new genomic test. Our previous research has shown that women's understanding of
recurrence risk as provided by genomic test results is strongly associated with both
hypothetical and actual treatment choices [11, 12]. These findings highlight the importance
of studying the patient's perspective of receiving and understanding test results based on
genomic information. Assessing patients' reactions to complex genomic risk information
may guide the development of communication strategies to support patient understanding
and adherence to treatment.
Our experimental study sought to examine patients' beliefs about how hypothetical genotype
information would affect their perceived recurrence risk. Given the known benefits of
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tamoxifen, we hypothesized that receipt of this treatment (hypothetical) would be associated
with a reduction in perceived recurrence risk. Furthermore, we hypothesized that patients
would expect a reduction in recurrence risk only in the setting of tamoxifen treatment; we
would not expect to find this relationship in the setting of no tamoxifen treatment.
Materials and Methods
Participants
In Lineberger Comprehensive Cancer Center trial 0801, women on tamoxifen for prevention
or treatment of breast cancer at a university hospital and several community clinics
underwent CYP2D6 genotyping. We have previously reported the methods for the pilot
study [13]. Patients with any intermediate or poor metabolizing (IM or PM) alleles received
increased tamoxifen doses of 40mg daily, but patients homozygous for extensive
metabolizing (EM) alleles received routine doses of 20 mg daily. The informed consent
document stated that the purpose of the study was to see if dose adjustment could raise
endoxifen concentrations in reduced metabolism patients, but that it was not clear whether
dose escalation would provide clinical benefit. In this embedded sub-study performed
between April 2009 and September 2010, patients completed a survey prior to receiving
their genotype.
Participants were women who had been taking tamoxifen for at least 4 months (but no more
than 4.5 years) to prevent or treat breast cancer (ductal carcinoma in-situ or invasive). The
trial included women with Eastern Cooperative Oncology Group (ECOG) performance
status of 0 to 2 and an expected survival of at least 6 months. Exclusion criteria were being
on any of the following CYP2D6 inhibiting medications: amiodarone, haloperidol, indinavir,
ritonavir, quinidine, duloxetine, paroxetine, bupropion, or fluoxetine. We collected these
data directly from patients and their treating physicians through medication review by the
nurse study coordinator.
Of 377 eligible patients, 320 patients completed the survey (85%), and 57 returned
incomplete surveys. Of the incomplete surveys, 32 had no data for the section of the survey
germane to this study, and 25 had partial data. Patients with incomplete survey data were
similar on all variables we examined compared to patients who completed the survey. Most
respondents who completed the survey were white (81%) and were on tamoxifen for
treatment of invasive breast cancer (85%) (Table 1); mean time on tamoxifen treatment was
16 months. Fewer patients (14%) had a DCIS diagnosis and were on tamoxifen for
prevention of recurrence. About one-third (32%) were premenopausal. Patients' actual
genotypes were 35% for EM, 58% for IM and 5% for PM.
Procedures
The University of North Carolina institutional review board reviewed and approved the
study. The informed consent document that all patients signed stated: “The purpose of this
research study is to learn if the increased dose of tamoxifen in intermediate and poor
metabolizers will have an effect on the patient's endoxifen level. It is possible you will
receive no benefit from participating in this study. Your participation will help us answer the
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question of whether we can raise the level of the active metabolite of tamoxifen in women
who otherwise do not break-down the drug as well, but it is not clear that this will actually
provide any benefit.”
We used a within-subjects experimental design to assess patients' beliefs about how
CYP2D6 genotype and tamoxifen treatment would affect patients' perceptions of breast
cancer recurrence risk. We asked them to evaluate 6 hypothetical vignettes prior to knowing
their genotype. We experimentally manipulated the vignettes to describe whether women
hypothetically received tamoxifen treatment (no or yes) and their hypothetical genotype
(EM, IM, PM). Use of hypothetical vignettes is a well-accepted methodology for
understanding response to new cancer testing [12, 14-15]. Vignettes used in our study
appear in the appendix.
Measures
The following instructions appeared at the top of the survey vignettes (Appendix A): “A
new genotype test can say how well your body uses (metabolizes) tamoxifen. Extensive
metabolizers (EM) may get the full benefit from tamoxifen. Intermediate metabolizers (IM)
may get some benefit from tamoxifen. Poor metabolizers (PM) may get the least benefit
from tamoxifen.” For each combination of genotype and tamoxifen treatment (independent
variables), participants indicated what they thought their chance of cancer recurrence would
be, from 0% to 100% (dependent variable). For example, the poor metabolizer/no tamoxifen
vignette read, “If you don't take tamoxifen and your genotype test shows you are a poor
metabolizer, what do you think would be your chance of recurrence?” The instructions
asked participants to give their best answer if they were unsure.
Data Analyses
We analyzed the data using a 3 (genotype) × 2 (receipt of tamoxifen) repeated measures
ANOVA, using two-tailed tests with a critical alpha of .05. Data met the assumptions for
repeated measures ANOVA, normality (Shapiro-Wilk, W=0.93) and homogeneity of
variance (Levene's test, p=0.13). We probed the interaction by looking at ANOVAs for
effect of genotype, for the two hypothetical tamoxifen treatment groups (received or did not
receive), using two-tailed Bonferroni-adjusted tests. We conducted sensitivity analyses
stratifying by actual genotype and type of breast disease (DCIS or invasive). Effect sizes are
reported partial eta-squared (η2) which can be interpreted as proportion of variance
explained. As data were completely within-subjects, controlling for participant
characteristics was unnecessary. Statistical analyses were performed with SAS version 9.3
statistical software (SAS Institute Inc., Cary, NC).
Results
Overall, patients expected tamoxifen to lower their breast cancer recurrence risk (RR) from
49% to 31% (F1, 638 = 92, p<.001) (Figure 1). Patients expected that being poorer
metabolizers, as indicated by genotype status, would increase recurrence risk (F2, 638 = 69,
p<.001). Risk perceptions were more sensitive to genotype if tamoxifen were prescribed
than if not (interaction, F2, 638 = 20, p<.001).
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For the setting of no tamoxifen treatment, patients believed that merely being able to
metabolize tamoxifen would provide no benefit in reducing their RR (shallow slope on the
left panel of Figure 1, partial η2=0.00). For the no-tamoxifen/EM condition, women
estimated their RR to be 47% on average, 48% in the no-tamoxifen/IM condition, and 53%
in the no-tamoxifen/PM condition. These three RRs were not statistically significantly
different from one another (p=0.06). Effects sizes for comparisons in the no-tamoxifen
treatment setting were partial η2 =.05 for EM vs IM; partial η2 =.15 for IM vs PM; and
partial η2 =.20 for PM vs EM.)
For the setting of tamoxifen treatment, patients believed that genotype would have an effect
on their RR (steep slope on right half of Figure 1, partial η2 =.08). For the tamoxifen/EM
condition, women estimated their RR to be 22% on average, 30% in the tamoxifen/IM
condition, and 40% in the tamoxifen/PM condition (p<.001). Each of these conditions
differed from one another (p<.001). Effects sizes for comparisons in the tamoxifen treatment
setting were partial η2 = .34 for EM vs IM; partial η2 = .40 for IM vs. PM; and partial η2 = .
71 for PM vs. EM.) Our sensitivity analyses showed the same pattern of findings (effect of
hypothetical genotype was present only in the setting of tamoxifen treatment) when
stratifying by patients' breast disease type (DCIS vs. invasive) and their actual genotype.
Null findings for the PM genotype subgroup may have been due to small cell sizes (n=16).
We also examined consistency in perceived RR for the three conditions with hypothetical
tamoxifen treatment. Most patients (n=228, 71%) responded that EM would have a lower
RR than IM. Some said that RR for EM and IM would be equal (n=65, 20%), but few said
that EM would have a higher RR than IM (n=27, 9%). Similarly, most patients (n=234,
73%) responded that IM would have a lower RR than PM. Some said that RR for IM and
PM would be equal (n=59, 19%), but again few said that IM would have a higher RR than
PM (n=27, 8%).
Discussion
Our data suggest that participants in pharmacogenomic trials may have a high expectation of
clinical benefit despite emphasis in informed consent documents on the scientific purpose of
the research and the uncertainty of any direct benefit. Women participating in our study
understood that tamoxifen reduced breast cancer risk. They also understood that, in the
absence of tamoxifen treatment, genotype alone had no effect on recurrence risk. However,
despite consent materials that described uncertainty about CYP2D6 benefit in clinical
decision making, the participants believed that this benefit was likely to be larger for
extensive metabolizers in the setting of tamoxifen treatment. Whether or not this benefit is
indeed larger for extensive metabolizers is an active area of scientific exploration and
controversy.
Our findings are consistent with previous research suggesting that patients are highly
receptive to genomic risk information [11,13,16]. Our previous study showed that women
placed more emphasis on genomic test results for predicting cancer recurrence risk
compared to standard pathological markers (e.g. cancer stage) when information from these
two sources conflicted [13]. These findings differ markedly from previous work on
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communicating with women about BRCA 1/2 mutations that found that women resisted
information from these tests, overestimating their actual risk [10]. It may be that women
think differently about information relevant to treatment for a current disease (e.g.,
CYP2D6) than they do about risk for future disease (e.g., BRCA 1/2).
Recent research has questioned whether high expectations of direct benefit, which patients
consistently report in oncology trials, are due to a “therapeutic misestimation” among
participants (suggesting that patients misunderstand the purpose of the trial, undermining the
validity of the informed consent process) or are expressions of optimism for the best
possible outcome [17-19]. Our study was not designed to test this complex question, but
highlights the potential for patients to misunderstand what new genomic tests can offer
[20,21]. This misunderstanding could bias patients to assume that genomic information is
valid, without understanding what is needed for tests to move into routine clinical care.
Also, the potential misunderstandings identified here may lead patients to request the test
from physicians and affect their willingness to take or continue tamoxifen in the absence of
clinical evidence to guide practice at this time.
Strengths and Limitations
Study strengths are the inclusion of patients who were part of an active clinical trial to adjust
tamoxifen dosing and a large clinical sample. Limitations include the use of hypothetical
vignettes, though we know of no other way to reasonably assess women's understanding of
the potential risk reduction associated with CYP2D6 genotype. It is unclear to what extent
that language in the survey instructions led patients to believe tamoxifen worked best (or
only) for extensive tamoxifen metabolizers (the vignette instructions reminded participants
to the purpose of the trial -- that poor metabolizers may get the least benefit from tamoxifen
treatment whereas extensive metabolizers may get the most benefit). Patients may have
responded to the vignettes differently had the survey not restated the potential benefit of
tamoxifen metabolizer status. Another interpretation is that responses to the vignettes
indicated that patients found the hypothesis tested in the trial to be credible. It is also
plausible that communications between the physicians and their patients about the purpose
of the trial could have influenced patients' beliefs. Lastly, patients from the clinics we
studied may be less diverse than patients from other clinical settings.
Clinical Implications
Patients are highly receptive to receiving genomic risk information. Our study adds to an
existing literature examining the lay population's beliefs about the clinical utility of new
genomic technology. Findings reinforce the importance of translating and communicating
the purpose of genomic trials to patients. Whether CYP2D6 testing will be clinically useful
in planning tamoxifen treatment for patients is a topic of active debate. While the oncology
community continues to explore this question, caution should be used when communicating
clinical utility and results of novel genomic assays to patients.
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Appendix A. Study vignettes
A new genotype test can say how well your body uses (metabolizes) tamoxifen.
• Extensive metabolizers may get the full benefit from tamoxifen.
• Intermediate metabolizers may get some benefit from tamoxifen.
• Poor metabolizers may get the least benefit from tamoxifen.
For each combination, please say what you think your chance of cancer recurrence would be
(from 0% to 100%, with 0% meaning your cancer will never come back). If you are unsure,
give your best answer.
If you and your genotype test shows you are a What do you think would be your chance ofrecurrence?
1. don't take tamoxifen extensive metabolizer _____ % chance
2. don't take tamoxifen intermediate metabolizer _____ % chance
3. don't take tamoxifen poor metabolizer _____ % chance
 4. take tamoxifen extensive metabolizer _____ % chance
 5. take tamoxifen intermediate metabolizer _____ % chance
 6. take tamoxifen poor metabolizer _____ % chance
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Effect of hypothetical genotype and tamoxifen treatment on perceived chance of breast
cancer recurrence. Error bars report standard errors.
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 White 42 (74%) 259 (81%)
 Other 15 (26%) 61 (19%)
Age in years, median (Q1-Q3) 52 (46-60) 52 (46-61)
Premenopausal 21 (37%) 101 (32%)
Reason for tamoxifen
 Treatment of invasive breast cancer 44 (77%) 272 (85%)
 Prevention of recurrence (DCIS) 10 (18%) 45 (14%)
Actual genotype
 EM 15 (26%) 111 (35%)
 IM 37 (65%) 184 (58%)
 PM 3 (5%) 16 (5%)
 UM/Unknown 2 (4%) 9 (3%)
Note. Patients returning complete and incomplete surveys had comparable demographic characteristics (all p<.05).
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